Top Companies in the Australia Medical Cannabis Market and their Offerings
Market Ecosystem Analysis
| Ecosystem Segment | Key Participants | Explanation |
| Technology Providers | MediPharm Labs, Cann Group, Little Green Pharma | Cannabis extraction, GMP manufacturing, formulation technologies, pharmaceutical processing |
| Product Manufacturers | Tilray Brands, Aurora Cannabis, Cann Group, Little Green Pharma, MedReleaf Australia, Althea Group | Manufacture and supply medical cannabis oils, capsules, dried flower and pharmaceutical-grade cannabinoid products |
| Service Providers | Montu, Alternaleaf, Cannatrek, Astrid Dispensary | Patient consultation, prescription access, dispensing, education, telehealth |
| Platform Providers | Montu, Alternaleaf, Cann I Help | Digital prescribing platforms, patient management systems, telehealth services |
| CROs/CDMOs | Novotech, Southern Star Research | Clinical trials supporting cannabinoid therapeutics and regulatory studies |
| Software Vendors | Montu Digital Platform, Best Practice Software, MedicalDirector | Prescription management, patient records, telehealth integration |
| Research Institutions | Lambert Initiative for Cannabinoid Therapeutics (University of Sydney), National Drug and Alcohol Research Centre (UNSW), University of Queensland | Clinical research, cannabinoid pharmacology, evidence generation |
| End-User Industries | Hospitals, Specialty Clinics, Community Pharmacies, Telehealth Providers | Primary channels for prescribing and dispensing medical cannabis |
Recent Developments in the Australia Medical Cannabis Market
- In May 2025, Curaleaf International, part of Curaleaf Holdings, Inc., a leading international provider of medical cannabis products, announced the launch of Curaleaf-branded products in Australia. This announcement creates the expansion of Curaleaf's presence in one of the world's fastest-growing medical cannabis markets and underscores its commitment to local partnership, clinical integrity, and patient care.
- In March 2026, Tilray Medical, a recognized global leader in medical cannabis and a division of Tilray Brands, Inc., announced its largest portfolio expansion in Australia to date. The prolonged medical cannabis offering reinforces Tilray Medical’s long-term commitment to the Australia market and supports increased patient access to regulated, healthcare-supported medical cannabis products.
- In June 2026, Khalifa Kush, GRAMMY and Golden Globe-nominated recording artist Wiz Khalifa, announced its continued international expansion with entry into the Australia medical cannabis market. Marking its sixth global market, Khalifa Kush will partner with leading cannabis company Endoca to bring its signature products to patients in Australia.
Competitive Landscape
| Tier 1 | ||||
| Company Name | Headquarters | Country | Why Relevant to This Market | Key Products/Services |
| Little Green Pharma Ltd. | West Perth, Western Australia | Australia | Australia's leading vertically integrated medical cannabis company with domestic cultivation, GMP manufacturing, and exports | Medical cannabis oils, dried flower, cannabinoid medicines |
| Cann Group Limited | Melbourne, Victoria | Australia | Pioneer Australian cultivator and manufacturer with large-scale GMP production | Medicinal cannabis products, APIs, pharmaceutical cannabis |
| Tilray Brands, Inc. | New York, New York | United States | Major supplier of approved medical cannabis products into Australia through extensive distribution network | Medical cannabis flower, oils, oral products |
| Aurora Cannabis Inc. | Edmonton, Alberta | Canada | Strong Australian pharmaceutical distribution and premium cannabis portfolio | Medical cannabis flower, oils, capsules |
| MedReleaf Australia Pty Ltd. | Melbourne, Victoria | Australia | One of Australia's largest prescription medical cannabis suppliers backed by Aurora | Prescription cannabis flower, oils, cannabinoid formulations |
| Tier 2 | ||||
| Company Name | Headquarters | Country | Why Relevant to This Market | Key Products/Services |
| Althea Group Holdings Ltd. | Melbourne, Victoria | Australia | Established supplier with broad physician network and pharmaceutical distribution | CBD oils, THC products, prescription cannabis |
| Cannatrek Ltd. | Melbourne, Victoria | Australia | One of Australia's largest domestic distributors and cultivators | Medical cannabis flower, oils, patient access services |
| MediPharm Labs Corp. | Barrie, Ontario | Canada | GMP cannabis extraction and pharmaceutical manufacturing supplying Australian market | Cannabis APIs, extracts, pharmaceutical ingredients |
| Cronos Australia | Melbourne, Victoria | Australia | Australian subsidiary commercializing premium cannabinoid medicines | Medical cannabis products |
| Bioxyne Limited | Sydney, New South Wales | Australia | Active importer, manufacturer, and distributor through Breathe Life Sciences | Pharmaceutical cannabis products |
| Tier 3 | ||||
| Company Name | Headquarters | Country | Why Relevant to This Market | Key Products/Services |
| Vitura Health Limited | South Brisbane, Queensland | Australia | Growing healthcare company integrating prescribing, dispensing and pharmacy services | Medical cannabis clinics, pharmacy services |
| Montu Group Pty Ltd. | Melbourne, Victoria | Australia | Rapidly growing digital medical cannabis ecosystem and patient platform | Alternaleaf telehealth, dispensing platform |
| ECS Botanics Holdings Ltd. | Ballarat, Victoria | Australia | Domestic GMP cultivator supplying pharmaceutical cannabis | Cannabis biomass, flower, extracts |
| BioCann Pty Ltd. | Southport, Queensland | Australia | Expanding supplier focused on affordable prescription cannabis | Cannabis flower, oils, prescription medicines |
| Ananda Developments Plc | London | United Kingdom | Expanding clinical cannabinoid portfolio with increasing Australian market collaborations | CBD therapeutics, cannabinoid pharmaceutical development |
Market Growth
The Australia medical cannabis market size was estimated at USD 1.02 billion in 2025 and is predicted to increase from USD 1.17 billion in 2026 to approximately USD 3.99 billion by 2035, expanding at a CAGR of 14.6% from 2026 to 2035.
Keypoints
- Company Overview
- Locations Subsidiaries/Geographic reach
- Key Executives
- Company Financials
- Patents registered
- SWOT Analysis
- Applications Catered
- Strategic collaborations
- Recent Developments
- Competitive Benchmarking